Taysha Gene Therapies has provided a corporate update on their two gene replacement lead programs: TSHA-120 for Giant Axonal Neuropathy and TSHA-102 for Rett syndrome. Below please find links to a community statement, recorded webcast, and press release.
The materials provide an update on Taysha’s REVEAL adult trial for Rett in Montreal, as well as plans to submit a clinical trial application in the UK and an IND in the US later this year.
The more than $10 million that RSRT has invested in gene replacement fueled the innovative Gene Therapy Consortium, through which Steve Gray, PhD, developed a mechanism to control the level of MECP2 expression that is part of TSHA-102. In addition, TSHA-102 delivers a shortened “mini-gene” version of the MECP2 gene, which was developed by Adrian Bird, PhD, and funded through RSRT’s MECP2 Consortium.
“We are tremendously grateful to all RSRT’s supporters and to families that fundraise for us,” said Monica Coenraads, RSRT CEO. “Without their actions, we would not be in this exciting stage.”
Taysha Webcast (Listen at 12:05-13:45 to hear the report out on timing for the first dosing of an adult patient in their clinical trial, timing of initial clinical data, pediatric trial application timing in the UK, and IND application timing in the US.)
What we learned from Taysha's November 2022 Clinical Trial Update